WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq:OSCI - News) today announced preliminary revenue results for the fourth quarter and fiscal year ended December 31, 2007. For the fourth quarter of 2007, the Company expects to record total revenues of approximately $25 million, with approximately $19 million from ANTARA® (fenofibrate) capsules and approximately $6 million in revenues related to FACTIVE® (gemifloxacin mesylate) tablets. These results compare to approximately $18 million in total revenues in the fourth quarter of 2006 and reflect nearly 40% growth.
